Clinical Trial Update: The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the impact of osmotic-release methylphenidate (OROS MPH) on families of children and adolescents with ADHD; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• OROS-Methylphenidate (osmotic-release methylphenidate) (methylphenidate)

Snippet

Sponsor: Johnson & Johnson Taiwan Ltd | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 4 | Status: COMPLETED | Results posted: 2014-04-08